Eventide reports 4.1% stake in Mirum Pharma

Mirum Pharmaceuticals, Inc. received an amended Schedule 13G showing that Eventide Asset Management, LLC, together with Finny Kuruvilla and Robin C. John, reports beneficial ownership of 2,093,582 shares of common stock, representing 4.1% of the class.

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. received an amended Schedule 13G showing that Eventide Asset Management, LLC, together with Finny Kuruvilla and Robin C. John, reports beneficial ownership of 2,093,582 shares of common stock, representing 4.1% of the class. Eventide has sole voting and dispositive power over these shares, while Kuruvilla and John report shared voting and dispositive power over the same amount. The group states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Mirum. The filers also expressly disclaim beneficial ownership of the securities covered by the statement and make a joint filing agreement under Rule 13d-1(k)(1).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Mirum Pharmaceuticals (MIRM) is reported in this Schedule 13G/A?

The filing reports beneficial ownership of 2,093,582 Mirum Pharmaceuticals common shares, equal to 4.1% of the outstanding class. This stake is reported jointly by Eventide Asset Management, Finny Kuruvilla and Robin C. John under an amended Schedule 13G.

Who are the reporting persons in the Mirum Pharmaceuticals (MIRM) Schedule 13G/A?

The reporting persons are Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John. They jointly report beneficial ownership in Mirum Pharmaceuticals common stock and have agreed in writing to file a single combined Schedule 13G under SEC Rule 13d-1(k)(1).

How is voting and dispositive power over Mirum (MIRM) shares allocated among the filers?

Eventide reports sole voting and sole dispositive power over 2,093,582 shares. Finny Kuruvilla and Robin C. John each report shared voting and shared dispositive power over the same 2,093,582 shares, with no sole voting or dispositive authority individually.

Is the Mirum Pharmaceuticals (MIRM) stake reported as a control-seeking position?

No. The filers certify the Mirum shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. They further state the holdings are not in connection with any transaction aimed at obtaining control.

Why does the Mirum (MIRM) Schedule 13G/A mention ownership of 5 percent or less?

Item 5 notes ownership of 5 percent or less of the class, consistent with the reported 4.1% stake. This indicates the filers’ holdings are below the 5% threshold often associated with larger reporting obligations under Section 13(d) of the Exchange Act.

Do the Mirum (MIRM) Schedule 13G/A filers disclaim beneficial ownership of the shares?

Yes. The statement says each person filing expressly disclaims beneficial ownership of the securities covered. It also clarifies that submitting the report should not be construed as an admission that any filer is the beneficial owner of the reported Mirum shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 01:09 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Mirum Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

604749101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 604749101

1

Names of Reporting Persons

Eventide Asset Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,093,582.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,093,582.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,093,582.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.1 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 604749101

1

Names of Reporting Persons

Finny Kuruvilla, M.D. Ph. D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,093,582.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,093,582.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,093,582.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.1 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 604749101

1

Names of Reporting Persons

Robin C. John

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,093,582.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,093,582.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,093,582.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.1 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Mirum Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 989 East Hillsdale Boulevard, Suite 300, Foster City, California 94404
Item 2.
(a)	Name of person filing: (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
(b)	Address or principal business office or, if none, residence: Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
(c)	Citizenship: Eventide: Delaware Kuruvilla: United States John: United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 604749101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Eventide: 2,093,582 (ii) Kuruvilla: 2,093,582 (iii) John: 2,093,582
(b)	Percent of class: (i) Eventide: 4.1% (ii) Kuruvilla: 4.1% (iii) John: 4.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Eventide: 2,093,582 (2) Kuruvilla: 0 (3) John: 0
	(ii) Shared power to vote or to direct the vote: (1) Eventide: 0 (2) Kuruvilla: 2,093,582 (3) John: 2,093,582
	(iii) Sole power to dispose or to direct the disposition of: (1) Eventide: 2,093,582 (2) Kuruvilla: 0 (3) John: 0
	(iv) Shared power to dispose or to direct the disposition of: (1) Eventide: 0 (2) Kuruvilla: 2,093,582 (3) John: 2,093,582
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	02/13/2026

Finny Kuruvilla, M.D. Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	02/13/2026

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	02/13/2026

Exhibit Information

EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them. Eventide Asset Management, LLC Date: February 13, 2026 By: /s/ Peter J. Luiso Name: Peter J. Luiso Title: General Counsel Date: February 13, 2026 Finny Kuruvilla, M.D., Ph. D. By: /s/ Finny Kuruvilla, M.D., Ph. D. Name: Finny Kuruvilla, M.D., Ph. D. Date: February 13, 2026 Robin C. John By: /s/ Robin C. John Name: Robin C. John